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Abstract
Chronic kidney disease (CKD) leads to uremia. CKD is characterized by a gradual increase
in kidney fibrosis and loss of kidney function, which is associated with a progressive
increase in risk of atherosclerosis and cardiovascular death. To prevent progression of both
kidney fibrosis and atherosclerosis in uremic settings, insight into new treatment options
with effects on both parameters is warranted. The GLP-1 analogue liraglutide improves glu-
cose homeostasis, and is approved for treatment of type 2 diabetes. Animal studies suggest
that GLP-1 also dampens inflammation and atherosclerosis. Our aim was to examine
effects of liraglutide on kidney fibrosis and atherosclerosis in a mouse model of moderate
uremia (5/6 nephrectomy (NX)). Uremic (n = 29) and sham-operated (n = 14) atherosclero-
sis-prone low density lipoprotein receptor knockout mice were treated with liraglutide
(1000 μg/kg, s.c. once daily) or vehicle for 13 weeks. As expected, uremia increased aortic
atherosclerosis. In the remnant kidneys from NX mice, flow cytometry revealed an increase
in the number of monocyte-like cells (CD68+F4/80-), CD4+, and CD8+ T-cells, suggesting
that moderate uremia induced kidney inflammation. Furthermore, markers of fibrosis (i.e.
Col1a1 and Col3a1) were upregulated, and histological examinations showed increased
glomerular diameter in NX mice. Importantly, liraglutide treatment attenuated atherosclero-
sis (~40%, p < 0.05) and reduced kidney inflammation in NX mice. There was no effect of lir-
aglutide on expression of fibrosis markers and/or kidney histology. This study suggests that
liraglutide has beneficial effects in a mouse model of moderate uremia by reducing athero-
sclerosis and attenuating kidney inflammation.
Introduction
Chronic kidney disease (CKD) leads to uremia, and is one of the strongest known risk factors
for cardiovascular death (CVD) [1, 2]. Presently, up to 10% of the general population are at
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increased risk of CVD due to decreased kidney function [3]. This number is believed to rise in
the coming years due to the increase in patients with type 2 diabetes. Thus, long standing dia-
betes is a risk factor for CKD [3].
CKD is characterized by a detrimental, self-reinforcing, process in which loss of kidney
function and subsequent kidney inflammation and fibrosis promotes disease progression to
end stage renal disease (ESRD) and ultimately death [4, 5]. Although kidney fibrosis is believed
to be driven by aberrant inflammatory processes, the exact mechanisms behind the progres-
sion from CKD to ESRD are not fully understood. Currently, there are no treatment options
available to lower kidney fibrosis [5, 6]. There is therefore a huge need for new treatments
aimed at attenuating fibrosis.
One of the main reasons for the increased risk of CVD in patients with CKD is acceleration
of atherosclerosis. Current treatment modalities aimed at reducing atherosclerosis are not suf-
ficiently effect-full in patients with reduced kidney function, and new treatment options are
therefore warranted. To investigate mechanisms accelerating atherosclerosis in uremia, we—
and others—have induced moderate uremia by 5/6 nephrectomy (NX) in hyperlipidemic mice
and shown that this increases atherosclerosis [7–9]. In normocholesterolemic rats and mice,
the NX model has also been applied to study kidney inflammation and fibrosis in moderate
uremia [10–13]. Studies investigating the effects on kidney inflammation and fibrosis in a
hypercholesterolemic setting are, however, highly warranted.
GLP-1 is mainly known for its role in glucose metabolism and appetite regulation, and
GLP-1 based therapies are approved for treatment of type 2 diabetes and obesity. A number of
studies suggest that GLP-1 has additional benefits. Thus, GLP-1 and GLP-1 analogues have
been shown to have anti-inflammatory properties in humans [14] and treatment with GLP-1
and GLP-1 analogues has decreased atherosclerosis in mouse models [15–17]. Moreover, pre-
vious studies have showed protective effects of GLP-1 analogues by attenuating albuminuria
and hyperfiltration in animal models of diabetes [18, 19].
The aim of the present work was to investigate whether induction of moderate uremia in
atherosclerosis-prone hyperlipidemic LDLr-/- mice induced not only atherosclerosis, but also
affected the renal phenotype of inflammation and fibrosis. If so, we wanted to address whether
the GLP-1 analogue liraglutide could attenuate these effects in uremic settings.
Results
Uremia accelerates atherosclerosis and kidney fibrosis in LDLr-/- mice
(Study 1)
To study the effects of uremia on atherosclerosis, kidney inflammation and fibrosis, moderate
uremia was induced by 5/6 NX in LDLr-/- mice. Uremia was induced in 13 weeks old female
LDLr-/- mice (NX) and LDLr-/- mice were sham-operated as controls (SHAM) (see study out-
line in S1 Fig). Seven weeks after induction of uremia, all mice received a cholesterol rich diet
(0.3% cholesterol and 4.25% fat) for 9 weeks. The study was terminated 16 weeks after induc-
tion of uremia. At this time point, plasma analyses indicated that NX induced a moderate
increase in plasma urea (~2.5 fold, P<0.0001) and creatinine (~1.5 fold, P<0.0001) concentra-
tions (S1 Table).
Aortic arch atherosclerosis was significantly increased in NX as compared to SHAM mice
(Fig 1). Flow cytometry analyses of the remnant kidney from NX mice and an anatomically
comparable kidney piece from SHAM mice revealed a reduction of endothelial and distal
tubular epithelial cells (DTECs) in the remnant kidneys from NX mice compared to SHAM
mice. The number of proximal epithelial cells (PTECs) was not affected (S2 Fig). Leukocyte
numbers were identical in SHAM and NX mice (S3 Fig) and based on the number of
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neutrophils, there was no sign of acute inflammation in the kidneys (data not shown). How-
ever, there was a trend, albeit not statistically significant, towards an increased number of
CD4+ T-cells in the remnant kidney from NX as compared to SHAM mice (p = 0.05), and a
similar not statistically significant trend for CD8+ T-cells (p = 0.10) (Fig 2A and 2B). Neither
monocyte-like (CD68+F4/80-) nor macrophage-like (CD68+F4/80+) cell numbers were
affected by NX (Fig 2C and 2D). Of interest, in the macrophage-like cell population, there was
a shift towards a pro-fibrotic M2-like phenotype with increased expression of the M2 marker
CD206 and decreased expression of the M1 marker CD11c (Fig 2E and 2F).
Gene expression analyses revealed an upregulation of fibrosis-related genes in the remnant
kidney of NX as compared to SHAM mice (Table 1). Thus, mRNA expression of Col1a1,
Col3a1, and Fn1 was significantly increased ~2-, ~2-, and ~4-fold, respectively. Moreover,
there was an upregulation of the kidney injury marker NGAL, while Wt1, a marker for podo-
cytes, was downregulated, altogether indicating kidney injury (Table 1). Notably, of the 8
inflammatory genes investigated, only Ccl12 was significantly upregulated by NX (~2.4-fold,
p<0.05) (Table 1).
Overall, the results obtained in Study 1 suggested that 5/6 NX in LDLr-/- mice provides a
suitable model for investigations of both atherosclerosis and the renal phenotype of inflamma-
tion and fibrosis, in relation to moderate uremia.
Liraglutide induces a modest weight reduction, but does not affect
plasma cholesterol concentrations in uremic mice (Study 2)
The GLP-analogue liraglutide has been shown to have beneficial effects on both atherosclerosis
and diabetic kidney disease in animal models (15, 19). To address whether liraglutide could
affect atherosclerosis and kidney damage in uremic LDLr-/- mice, we induced moderate ure-
mia by NX in 11–12 weeks old LDLr-/- mice and included SHAM-operated controls (Study 2)
(see study outline in S1 Fig). Prior to initiation of liraglutide treatment, plasma urea and creati-
nine concentrations were increased ~3-fold (S2 Table). NX mice were divided into 2 separate
groups matched by weight, cholesterol, and urea concentrations. Two weeks after induction
of uremia, injections of liraglutide (once daily) or vehicle (once daily) were initiated and
Fig 1. Uremia accelerates atherosclerosis in LDLr-/- mice. Uremic (NX; n = 10) and control (SHAM; n = 10)
LDLr-/- mice were put on a western type diet for 9 weeks after induction of uremia. Atherosclerosis was determined
as the relative plaque area in % of the total aortic arch area. Depicted values are mean±SEM. *p<0.05 as
determined by unpaired students t-test.
doi:10.1371/journal.pone.0168396.g001
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Fig 2. Immune cell composition is changed in kidneys from uremic LDLr-/- mice. Sixteen weeks after
induction of uremia, flow cytometry was performed on kidneys from control (SHAM) and uremic (NX) LDLr-/- mice
(n = 5 mice/group). The number of CD4+ T-cells (A), CD8+ T-cells (B), monocyte-like (CD68+F4/80-) and
macrophage-like (CD68+F4/80+) cells (C and D) relative to kidney weight is depicted. On macrophage-like cells,
median fluorescent intensity (MFI) for the M1 marker CD11c (E) or the M2 marker CD206 (F) was detected.
Depicted values are mean±SEM. *p<0.05 as determined by unpaired students t-test.
doi:10.1371/journal.pone.0168396.g002
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Table 1. Gene expression depicted asΔCT and fold change relative to control (SHAM). Results are
shown as (mean±SEM).
Gene name SHAM NX NX rel to SHAM
ΔCT ΔCT mean fold change
Fibrosis
Col1a1 5.74±0.10 4.75±0.19 2.04±0.34*
Col1a2 5.26±0.12 4.88±0.17 1.31±0.17
Col3a1 5.99±0.14 4.95±0.18 2.08±0.31*
Ctgf 2.26±0.07 2.36±0.19 0.96±0.12
Fn1 5.39±0.11 3.51±0.30 4.04±0.98*
Serpine1 7.74±0.14 7.26±0.14 1.36±0.14*
Tgfb1 6.71±0.08 6.77±0.18 0.99±0.14
Tgfb2 7.90±0.11 7.73±0.16 1.13±0.11
Tgfb3 9.46±0.12 8.78±0.16 1.63±0.23*
Snai1 8.17±0.26 9.11±0.25 0.47±0.07*
Vim 4.68±0.19 4.12±0.20 1.42±0.20
Pdgfb 5.82±0.10 5.93±0.16 0.94±0.12
Pdgfrb 4.53±0.09 4.87±0.11 0.79±0.06*
Adhesion molecules
Cdh1 3.72±0.06 4.01±0.14 0.83±0.09*
Cdh5 4.60±0.09 4.56±0.12 1.03±0.09
Itga1 4.60±0.12 4.65±0.10 0.96±0.07
Itga3 6.22±0.06 6.66±0.08 0.74±0.04*
Itga5 7.84±0.12 8.06±0.15 0.86±0.10
Extracellular matrix
Hspg2 4.95±0.13 5.10±0.06 0.88±0.03
Lamc1 6.60±0.11 6.75±0.10 0.89±0.06
Mmp2 7.99±0.13 7.33±0.21 1.61±0.23*
Timp1 11.28±0.12 10.15±0.14 2.18±0.20*
Timp2 4.05±0.09 4.00±0.13 1.04±0.10
Kidney injury
Cdkn1a 7.53±0.16 7.16±0.19 1.27±0.16
Havcr1 10.51±0.25 9.93±0.37 1.54±0.39
Lcn2 (NGAL) 7.50±0.14 4.99±0.21 5.76±0.88*
Wt1 7.43±0.11 8.09±0.08 0.62±0.03*
Nphs1 6.89±0.09 7.33±0.12 0.74±0.07*
Inflammation
Tlr2 8.19±0.12 7.79±0.20 1.35±0.22
Tnf 11.85±0.16 11.29±0.34 1.62±0.49
Ccl12 9.98±0.19 8.70±0.25 2.42±0.43*
Ccl2 9.49±0.24 8.84±0.26 1.52±0.34
Ccl5 8.43±0.28 8.42±0.38 0.99±0.23
Cxcl15 14.78±0.55 13.55±0.38 2.08±0.68
Icam1 7.95±0.17 8.12±0.24 0.90±0.16
Vcam1 7.08±0.07 6.68±0.24 1.39±0.23
BMP system
Grem1 12.53±0.20 9.86±0.34 6.66±1.26*
Kcp 9.46±0.10 9.29±0.16 1.14±0.13
Hypoxia
(Continued )
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maintained for 13 weeks. The dose of liraglutide was slowly increased during the first 2 weeks
to minimize effects of liraglutide on food intake. When the full dose was reached (1000 μg/kg),
mice were switched to cholesterol enriched diet. The study was terminated 15 weeks after
induction of uremia. Measurements of plasma liraglutide concentrations during the study
showed that liraglutide did not accumulate in the blood of NX mice (liraglutide concentration
in plasma after 2 weeks: 191±21 nM; 8 weeks: 252±20 nM; and at termination: 250±25nM;
p = ns). Furthermore, liraglutide treatment did not affect plasma glucose concentrations (S4
Fig).
At termination, liraglutide had not affected plasma urea, creatinine, or cholesterol concen-
trations (S2 Table). There was a small, yet statistically significant, weight difference between
the NX LIRA group and the NX control group at study termination (S2 Table). Also, a graphi-
cal depiction suggested a lower accumulated food intake in the NX LIRA group (S5 Fig).
Indeed, this was significant if the food intake was estimated as food intake per day per group
normalized to the number of mice in each group (SHAM: ~2.5 g/day, NX: ~2.7 g/day, NX
LIRA: ~2.4 g/day, p = 0.002, one-way ANOVA).
Liraglutide attenuates atherosclerosis in uremic mice but has only minor
effects on vascular inflammation
Atherosclerosis was assessed in the aortic arch en face. Unexpectedly, there was no statistically
significant increase in plaque formation in NX mice compared to SHAM mice (Fig 3A).
Table 1. (Continued)
Gene name SHAM NX NX rel to SHAM
ΔCT ΔCT mean fold change
Hif1a 2.82±0.05 2.78±0.08 1.03±0.06
Nos2 10.84±0.11 10.87±0.27 1.05±0.23
Nos3 7.90±0.09 8.32±0.13 0.75±0.07*
Rage
Ager 10.56±0.11 10.67±0.10 0.91±0.06
RAAS
Ace 4.10±0.13 4.32±0.13 0.84±0.08
Agt 4.78±0.11 4.15±0.17 1.56±0.22*
* p<0.05 relative to SHAM as determined by unpaired students-t test.
n = 6 (NX) and 10 (SHAM). Col1a1: Collagen, type I, alpha 1, Col1a2: Collagen, type I, alpha 2, Col3a1:
Collagen, type III, alpha 1, Ctgf: Connective tissue growth factor, Fn1: Fibronectin 1, Tgfb1: Transforming
growth factor beta 1, Tgfb2: Transforming growth factor beta 2, Tgfb3: Transforming growth factor beta 3,
Snai1: Snail family zinc finger 1, Vim: Vimentin, Pdgfb: Platelet-derived growth factor subunit B, Pdgfrb:
Platelet derived growth factor receptor beta, Cdh1: Cadherin 1, Cdh5: Cadherin 5, Itga1: Integrin subunit
alpha 1, Itga3: Integrin subunit alpha 3, Itga5: Integrin subunit alpha 5, Hspg2: Heparan sulfate proteoglycan
2, Lamc1: Laminin subunit gamma 1, Mmp2: Matrix metallopeptidase 2, Timp1: Tissue inhibitor of
metalloproteinase 1, Timp2: Tissue inhibitor of metalloproteinase 2, Cdkn1a: Cyclin-dependent kinase
inhibitor 1a, Havrc1: Hepatitis A virus cellular receptor 1, Lcn2: Lipocalin-2, Wt1: Wilms tumor 1, Nphs1:
Nephrin, Ccl2: Chemokine (C-C motif) ligand 2, Tlr2: Toll like receptor 2, Tnf: Tumor necrosis factor, Ccl12:
Chemokine (C-C motif) ligand 12, Ccl2: Chemokine (C-C motif) ligand 2, Ccl5: Chemokine (C-C motif) ligand
5, Cxcl15: Chemokine (C-X-C motif) ligand 15, Icam1: Intercellular adhesion molecule 1, Vcam1: Vascular
cell adhesion molecule 1, Grem1: Gremlin 1, Kcp: Kielin/chordin-like protein, Hif1a: Hypoxia inducible factor
1, alpha subunit, Nos2: Nitric oxide synthase 2, Nos3: Nitric oxide synthase 3, Ager: Advanced glycosylation
end product-specific receptor, Ace: Angiotensin I converting enzyme, Agt: Angiotensinogen
doi:10.1371/journal.pone.0168396.t001
Effects of Liraglutide Treatment in Uremic Mice
PLOS ONE | DOI:10.1371/journal.pone.0168396 December 16, 2016 6 / 21
However, when examining ‘mildly uremic’ (plasma urea<20 mM) as compared to ‘moderately
uremic’ (plasma urea>20 mM) mice, we detected a 1.5 fold uremia-mediated acceleration of
atherosclerosis in ‘moderately uremic’ as compared to SHAM mice (p = 0.02, Fig 3B). Impor-
tantly, liraglutide significantly attenuated plaque formation regardless of whether the statistical
analyses included all uremic mice or only ‘moderately uremic’ mice (Fig 3A and 3B).
To address whether the effect of liraglutide was paralleled by changes in vascular inflamma-
tion, aortic gene expression analyses and flow analyses of aortic immune cells were performed.
Although there was a non-significant trend towards lower leukocyte numbers in liraglutide
treated mice in the aortic wall (S6A Fig), there were no significant changes in the myeloid or
lymphoid composition, or in macrophage polarization markers (S6B–S6D Fig). Also, aortic
mRNA expression of the inflammatory markers MCP-1, VCAM-1, and iNOS was not affected
by liraglutide treatment (data not shown).
NX increased the plasma concentration of both pro- (OPN, IFNγ and TNFα) and anti-
inflammatory cytokines (IL-10). These analyses did not reveal effects of liraglutide on plasma
cytokine concentrations in NX mice (S3 Table).
Inflammatory changes induced by NX in the kidney is attenuated by
liraglutide
To determine effects of liraglutide on kidney inflammation and fibrosis, we used a combina-
tion of flow cytometry, gene expression, and histology. The number of endothelial cells,
DTECs, and PTECs was decreased in NX as compared to SHAM mice. Liraglutide had no
effect on these parameters in NX mice (S7 Fig).
The inflammatory profile of the NX remnant kidney was roughly similar to that seen in
Study 1; i.e. absence of acute inflammation as determined by the number of neutrophils (data
not shown), increased CD4+ and CD8+ T-cells (Fig 4A and 4B), and identical number of mac-
rophage-like cells. Also, there was a skewing of the macrophage-like cells towards a more pro-
fibrotic M2 like phenotype (Cd11clowCD206high) in both studies (Fig 4D–4F). In addition,
there was increased numbers of total leukocytes (S8 Fig) and monocyte-like cells (Fig 4C).
Interestingly, liraglutide treatment reduced the number of monocyte-like cells (Fig 4C).
Fig 3. Liraglutide attenuates atherosclerosis in uremic LDLr-/- mice. Uremic LDLr-/- mice were treated with vehicle (NX;
n = 14) or liraglutide (NX LIRA; n = 15) and sham operated control LDLr-/-mice were treated with vehicle (SHAM; n = 14). After 11
weeks of treatment with full dose (1000 μg/kg), atherosclerosis was quantified as the relative plaque area in % of the total aortic
arch area in all mice (A) and in NX mice with urea levels >20 (B). Depicted values are mean±SEM. *p<0.05 as determined by
1-way ANOVA followed by Sidak’s multiple comparisons post-test. n = 14–15 mice per group.
doi:10.1371/journal.pone.0168396.g003
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Fig 4. Liraglutide attenuates NX mediated kidney inflammation in LDLr-/- mice. A-F: flow cytometry analysis of
kidneys from control (SHAM; n = 7), uremic (NX; n = 7) or liraglutide treated uremic (NX LIRA; n = 7) LDLr-/- mice showing
the number of CD4+ T-cells (A), CD8+ T-cells (B), monocyte-like (CD68+F4/80-) and macrophage-like (CD68+F4/80+)
cells (C and D) relative to kidney weight. On macrophage-like cells, median fluorescent intensity (MFI) for the M1 marker
CD11c (E) or the M2 marker CD206 (F) was detected. Depicted values are mean±SEM. *p<0.05, **p<0.01, ***p<0.005
as determined by 1-way ANOVA followed by Sidak’s multiple comparisons post-test. n = 6 mice per group.
doi:10.1371/journal.pone.0168396.g004
Effects of Liraglutide Treatment in Uremic Mice
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Furthermore, there was a non-significant attenuation of leukocyte, CD4+T-cell, and CD8+ T-
cell, infiltration after liraglutide treatment (S8 Fig, Fig 4A and 4B), while expression of neither
the M1 nor the M2 marker on macrophage-like cells was altered (Fig 4E and 4F).
Gene expression of kidney injury markers and selected key fibrosis related genes revealed
changes in Col1a1, Col3a1, Fn1, Lcn2, and Havcr1 in NX compared to SHAM mice that were
reminiscent of those seen in Study 1 (Table 1). There was no effect of liraglutide treatment on
gene expression in NX mice (Table 2). Histological analyses of kidney sections showed an
increase in glomerular size in NX as compared to SHAM mice (Fig 5A and 5B), whereas colla-
gen deposition in the kidney cortex was not affected by NX (Fig 5A and 5C). Liraglutide did
not affect these histological measures (Fig 5A–5C).
Discussion
In this study, we have established that hypercholesterolemic 5/6 nephrectomized (NX) mice
can be used to study both uremia mediated acceleration of atherosclerosis and a renal pheno-
type of inflammation and early fibrotic changes. We show that treatment with the GLP-1 ana-
logue liraglutide attenuates atherosclerosis and infiltration of monocyte-like cells in the kidney
in uremic mice. Moreover, we find a tendency to less infiltration of CD4+ and CD8+ T cells in
kidneys from liraglutide treated uremic mice.
NX effects on the (remnant) kidney
Uremia promotes progressive kidney injury and fibrosis. Inflammation is central in the
fibrotic process, since an aberrant inflammatory stimulus drives the activation of fibroblasts
leading to extracellular matrix deposition. In this study, remnant kidneys from 5/6 NX
LDLr-/- mice were carefully examined to establish the inflammatory and fibrotic status in
moderate uremia. We established that this model is characterized by inflammatory cell infiltra-
tion (i.e. more CD4+ and CD8+ T cells as well as a marked shift towards more pro-fibrotic
Table 2. Gene expression depicted asΔCT and fold change in NX relative to control (SHAM) in column 4 and in NX LIRA relative to NX in column 5.
Results are shown as mean±SEM.
Gene name SHAM NX NX LIRA NX rel. to SHAM NX LIRA rel. to NX
ΔCT ΔCT ΔCT mean fold change mean fold change
Fibrosis
Col1a1 2.01±0.31 0.29±0.28 0.29±0.30 3.22±0.66** 1.05±0.24
Col3a1 3.77±0.18 1.72±0.11 1.68±0.15 4.02±0.30**** 1.04±0.10
Fn1 2.77±0.41 0.17±0.56 0.78±0.29 7.55±2.79** 0.48±0.09
Kidney injury
Cdkn1a 6.45±0.33 5.00±0.35 5.13±0.36 2.80±0.65 0.98±0.29
Havcr1 10.88±0.29 9.16±0.28 8.43±0.50 3.22±0.61* 2.25±0.75
Lcn2 (NGAL) 7.21±0.07 3.03±0.47 3.06±0.29 25.58±10.11**** 0.82±0.21
Wt1 6.81±0.13 7.02±0.14 6.97±0.15 0.86±0.08 1.05±0.10
Nphs1 7.18±0.14 6.97±0.11 7.01±0.15 1.14±0.09 0.99±0.11
* p<0.05,
** p<0.01,
*** p<0.005
**** p<0.0001 relative to SHAM as determined by 1-way ANOVA followed by Sidak’s multiple comparisons post-test.
n = 7–8 mice per group. Col1a1: Collagen, type I, alpha 1, Col3a1: Collagen, type III, alpha 1, Fn1: Fibronectin 1, Cdkn1a: Cyclin-dependent kinase inhibitor
1a, Havrc1: Hepatitis A virus cellular receptor 1, Lcn2: Lipocalin-2, Wt1: Wilms tumor 1, Nphs1: Nephrin, Ccl2: chemokine (C-C motif) ligand 2.
doi:10.1371/journal.pone.0168396.t002
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Fig 5. Uremia increases glomerular size, but not cortical collagen content in LDLr-/- mice. Representative pictures of kidney sections from
control (SHAM), uremic (NX) and liraglutide treated uremic (NX LIRA) mice stained with Massons trichrome (A). Scale bar = 200 μm for top row and
100 μm for bottom row. Glomerular diameters were measured (B) (25–49 glomeruli were assessed per kidney, n = 7–8 in each group) and collagen
deposition in the kidney cortex was quantified (C) (n = 5–7 in each group) using the Visiopharm software. **p<0.01, as determined by 1-way ANOVA
followed by Sidak’s multiple comparisons post-test.
doi:10.1371/journal.pone.0168396.g005
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M2-like macrophages) in NX compared to SHAM mice. Moreover, induction of uremia
increased expression of fibrosis-related genes, most importantly Col1a1, Col3a1, and Fn1. This
apparent pro-fibrotic environment in the NX mice did not lead to increased fibrosis as deter-
mined by collagen deposition in the kidney cortex, though we detected an increased glomeru-
lar diameter suggesting a response to the inflammatory environment [20]. This latter
observation may also simply reflect a compensatory increase to maintain glomerular filtration
after removal of 5/6 of the kidney tissue. One explanation for the lack of induction of fibrosis
may be the use of C57Bl6/j mice. While 5/6 NX in both rats and FVB/N mice results in both
glomerulosclerosis and tubulointerstitial fibrosis [21, 22], the C57Bl6/j strain, which is the only
background strain that readily develops atherosclerosis, is more resistant to kidney fibrosis
[21, 23]. Similarly, a recent study by Ghosh et al also did not detect increased fibrosis in this
model [24]. Furthermore, previous studies in our group [8, 25, 26] have established that kidney
function after 5/6 NX does not deteriorate progressively with time (up to 1 year) in C57Bl6/J
mice. It is therefore possible that 5/6 NX on a C57Bl6/J background merely reflect early stages
of kidney injury, incl. inflammatory cell infiltration, ‘fibrotic’ gene expression, and increased
glomerular diameter.
To our knowledge, we are amongst the first to document the effects of NX on the inflamma-
tory state in remnant kidneys from hypercholesterolemic mice. Such a setting is highly relevant
since it enables examination of effects on atherosclerosis (which requires hypercholesterol-
emia) and kidney damage in the same model.
Liraglutide effects in whole animals
Since GLP-1 analogues have been shown to have beneficial effects on both classical atheroscle-
rosis and kidney injury, we analyzed whether there might be effects of liraglutide on both ath-
erogenesis and kidney damage in NX mice. Although there was a tendency to lower creatinine
levels in NX mice treated with liraglutide, treatment did not affect plasma biochemistry;
including urea, Ca2+, phosphate, and cholesterol levels. Also, we did not detect accumulation
of liraglutide in NX mice, despite the relatively high dose given. Similar to what has been
found in a previous study addressing plaque formation in ApoE-/- mice, we found that liraglu-
tide treatment resulted in a slightly lower body weight (15). Furthermore, liraglutide treatment
resulted in a minor reduction in food intake. However, we did not detect any difference in
plasma cholesterol concentrations, and it is therefore unlikely that the attenuating effects of lir-
aglutide on uremic atherosclerosis are caused by the slight reduction in food intake.
Liraglutide effects on uremic atherosclerosis
We show that treatment with a GLP-1 analogue significantly attenuates atherosclerosis in a
uremic setting. Previously, mouse studies have shown that native GLP-1 and GLP-1 analogues
attenuate atherosclerosis [15–17], and it has been hypothesized that this might be caused by
decreased vascular inflammation [15, 17, 27, 28]. Thus, it has been suggested that the effect of
GLP-1 analogues on atherosclerosis is mediated via decreased macrophage influx [17, 27].
Despite a statistically non-significant trend towards lower leukocyte numbers in liraglutide as
compared to saline treated NX mice, we did not see effects of liraglutide on myeloid or lym-
phoid cell composition in the aorta. Furthermore, liraglutide treatment does not affect plasma
cytokine levels or inflammatory gene expression in the aorta for the parameters we have inves-
tigated. Taken together, this suggests that the effect of liraglutide on uremic atherosclerosis is
not driven by attenuation of vascular inflammation.
Alternatively, based on the observation that GLP-1 or a GLP-1 analogue reduces cholesterol
accumulation in macrophages, it could be speculated that liraglutide treatment results in less
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uptake or increased efflux of cholesterol in macrophages and hence attenuated foam cell for-
mation [16, 29]. Also, GLP-1 receptors are present on vascular smooth muscle cells (VSMCs).
VSMCs likely play an important role in plaque progression and perhaps even more so in ure-
mia. Thus, up to 30% of all lesion cells are derived from VSMCs [30] and uremia promotes a
phenotypic switch towards a pro-atherogenic aortic VSMC phenotype [31, 32] and unpub-
lished data from our group. Thus, the present anti-atherogenic effect of liraglutide could reflect
direct effects on macrophages, VSMCs, or both cell types. Further studies are needed to reveal
such mechanisms.
Liraglutide effects on the remnant kidney in NX mice
Macrophages affect kidney disease progression and fibrosis [5, 33]. Ablation of macrophages
—or inhibition of macrophage influx—attenuates kidney injury and fibrosis [34–36]. Further-
more, infiltration of CD4+ and CD8+ T-cells seemingly is also important in kidney disease pro-
gression [13, 36–39], although contradictory results regarding the role of CD4+ T cells exist
[40] and the exact role(s) played by inflammatory cells in kidney fibrosis is not delineated.
In the present study, NX led to a more pro-fibrotic environment in the remnant kidney,
characterized by more CD4+ and CD8+ T cells, increased infiltration of monocyte-like (CD68+
F4/80-) cells and a skewing of macrophage profiles towards more M2-like, and less M1-like
cells. Importantly, liraglutide tended to lower levels of CD4+ and CD8+ T cells as well as mac-
rophage numbers in the remnant kidney after NX. In line with this observation, Kodera et al,
reported that treatment of diabetic rats with the GLP-1 analogue exendin-4 attenuated macro-
phage infiltration in the kidney [19]. These authors also found that treatment with exendin-4
in NX rats resulted in reduced glomerular diameter and reduced deposition of type IV collagen
[19]. Similar results have recently been shown in non-diabetic 5/6-nephrectomised rats treated
with the dipeptidyl peptidase inhibitor linagliptin [41]. We did not detect effects of liraglutide
on glomerular size, or expression of fibrosis markers. This was somewhat surprising, since we
would have assumed that inflammation would precede an increased expression of pro-fibrotic
genes and glomerular diameter—ultimately leading to kidney fibrosis. The lack of liraglutide
effect could, however, be a matter of the severity of the induced kidney disease. Thus, we
did not detect increased fibrosis in NX mice, despite infiltration of inflammatory cells and
increased pro-fibrotic gene expression and glomerular diameter. Combined with the observa-
tion that kidney function does not get progressively worse with time in the 5/6 NX model on a
C57BL6/J background, our results suggest that the LDLr-/- NX model is mimicking very early
stages of kidney disease similar to mice with streptozotocin-induced diabetes [42, 43].
Summary and conclusion
The present study suggests that 5/6 nephrectomy of hypercholesterolemic LDLr-/- mice pro-
vides the opportunity to analyze effects of a given treatment on both atherosclerosis and kid-
ney damage. Furthermore, we show that liraglutide reduces atherosclerosis and inflammatory
cell infiltration in the kidney of LDLr-/-mice in uremic settings, thus highlighting a potential
additional effect of this GLP-1 analogue. The clinical importance of these findings is however
unknown.
Methods
LDLr-/- mice: Nephrectomy, diet, and liraglutide treatment
Female LDLr-/- mice (B6.129S7-Ldlrtm1Her/J, The Jackson Laboratory, Bar Harbor, USA)
were housed under a 12 hour light/dark cycle with water and food ad libitum. Ten-to-thirteen
Effects of Liraglutide Treatment in Uremic Mice
PLOS ONE | DOI:10.1371/journal.pone.0168396 December 16, 2016 12 / 21
weeks old mice were subjected to 5/6 nephrectomy (NX), as previously described [7, 8] to
induce mild to moderate uremia. Briefly, 5/6 nephrectomy was achieved in a 2-step operation.
The 2 poles of the right kidney were removed in the 1st operation, while the entire left kidney
was removed 2 weeks later. Control LDLr-/- mice were sham-operated. Mice where anesthe-
tized with either a mixture of fentanyl (0.079 mg/mL), fluanisone (2.5 mg/mL), and midazolam
(1.25 mg/mL) (hypnorm/dormicum) at a dose of 0.01 mL/g mouse or Zoletil (tiletamin 1.63
mg/mL, zolazepam 1.63 mg/mL, xylazin, 2.61 mg/mL, butorphanoltartrat 0.065 mg/mL) at a
dose of 0.01 mL/g mouse, and analgesia was administered by subcutaneous injection of bupre-
norphine (0.05 mg/kg mouse) for 2–3 days. Mice were monitored closely during the surgery
and in the following days.
Two studies were conducted. In study 1, mice were put on a cholate–free Western type diet
with 0.3% cholesterol and 4.25% fat (D01061402, Brogaarden) 7 weeks after the 2nd operation
and the study was terminated 9 weeks later, i.e. 16 weeks after NX induction. In study 2, injec-
tions of either liraglutide or saline control (s.c. once daily) were initiated 2 weeks after the 2nd
operation and for the remainder of the study. To minimize effects of liraglutide on food intake,
the liraglutide dose was slowly increased over a 2 week period until a final dose of 1000 μg/kg
was reached. From the initiation of liraglutide or vehicle (20 mM phosphate, 130 mM NaCl,
0.05% tween 80, pH = 7.4) injections, respectively, food intake was measured daily by weighing
the food from each cage, while the weight of each mouse was determined weekly. These weekly
measurements were used to adjust the dosage of liraglutide. When the full liraglutide dose was
reached (4 weeks after the 2nd surgery), mice were put on the Western type diet detailed above.
The study was terminated after 11 weeks on the western type diet (15 weeks after the 2nd sur-
gery). Following the 2nd surgery, blood samples were collected after 1½ weeks (just before lira-
glutide treatment was initiated), 4 weeks (before western type diet), and 9 weeks (approximately
in the middle of the diet period). In both study 1 and study 2 mice received chow diet prior to
the western type diet.
In Study 1 (n = 40 mice in total), five mice died in connection with the surgical procedures,
one mouse died when doing IPGTT and two mice were found dead (unknown reason). One
mouse had a wound that required topical application of fucidin (2% fucidic acid) or fuciderm
(0.5% fucidic acid, 0.1% w/w betamethasone). In Study 2 (n = 61 mouse in total), five mice
died in relation to the surgical procedures, seven mice were euthanized due to wounds (caused
by fighting and/or scratching/licking), two mice died during sampling of blood and four mice
were euthanized due to humane endpoints (weight loss or general physical well-being). Three
mice had wounds that required topical application of fucidin (2% fucidic acid) or fuciderm
(0.5% fucidic acid, 0.1% w/w betamethasone).
Termination of the in vivo experiments
At termination, mice were anesthetized with Zoletil (as described above), and perfused with ice-
cold saline. The aortic arch was carefully dissected free from the heart and down to the 7th rib,
and pictures were taken for en face measurements. In study 2, aortas were subsequently placed
in either ice-cold PBS for flow analysis or snap frozen in liquid nitrogen for RNA extraction.
The kidney/kidney remnant from all mice was carefully dissected free from the surround-
ing tissue, and either placed in University of Wisconsin cold-storage solution (UW solution)
for flow analysis, snap frozen and stored at -80˚C for RNA quantification, or fixed in 4% para-
formaldehyde (PFA) for 24 hours and paraffin embedded for histology.
In study 2, the kidneys that were not used for flow cytometry were carefully cut into 2
through the midline and preserved for RNA quantification (snap frozen) or histology (embed-
ding in Tissue-tek and frozen).
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Ethical permission
All experiments were performed according to the principles stated in the Danish law on ani-
mal experiments and were approved by the Animal Experiment’s Inspectorate, Ministry of Jus-
tice, Denmark (approval no. 2013-15-2934-00843). The investigation conforms to the Guide
for the Care and Use of Laboratory Animals published by the European Parliament [EU direc-
tive 2010/63/EU].
En face measurements of atherosclerosis
Aortas were opened longitudinally and pictures were taken with the IM50 software (Leica).
Relative atherosclerotic plaque area was calculated as plaque area relative to total aortic arch
surface area using the image analyses software Visiopharm (Visiopharm, Denmark).
Plasma measurements
Blood was collected in either EDTA or heparinized microtubes and centrifuged at 4000 rpm
for 10 min at 4˚C. Plasma urea, creatinine, cholesterol, total calcium, and phosphate were mea-
sured with a Cobas1 8000 modular analyzer series (Roche A/S). For plasma glucose concen-
trations, plasma samples were pooled two and two and measured with a Cobas1 8000
modular analyzer series (Roche A/S).
Plasma osteopontin was measured by ELISA (Quantikine, MOST00; R&D systems), MCP-
1 was measured by alphaLISA (AL509C; Perkin Elmer). TNFα, KC, IL-6, IFNγ, IL-10, and IL-
5 were measured with a V-PLEX Proinflammatory Panel 1 (mouse) Kit from MSD (MESO
Scale Diagnostics, K15048D). Liraglutide was measured by the assay department at Novo Nor-
disk using the AlphaScreen technology (Perkin Elmer, Denmark).
RNA extraction and qPCR
In study 2, RNA was extracted form aortas using the Trizol reagent (Invitrogen). cDNA was
generated using High Capacity cDNA Reverse Transcription Kit (Applied Biosystems) and
analyzed with Fast SYBR 1 Green Master Mix on an ABI 7900 HT sequence detection system
(Applied Biosystems™, CA, USA) using 1 ng of RNA/reaction.
RNA was extracted from kidney/kidney remnant using Trizol (Invitrogen) followed by
RNeasy spin columns. Of note, both poles on the right kidney from SHAM mice were
removed before RNA extraction to ensure extraction from anatomically similar pieces in NX
and SHAM mice. RNA concentration was determined by Nanodrop (Thermo Scientific). In
Study 1, cDNA was made from 500 ng RNA using High Capacity cDNA Reverse Transcrip-
tion Kits (Applied Biosystems) and gene expression was analyzed with a Custom TaqMan1
Array Card (Life Technologies) using TaqMan1 Gene Expression Master Mix (Thermo-
Fisher Scientific) (500 ng RNA/sample corresponding to 10 ng RNA/reaction). Assay ID for
each of the genes is listed in S4 Table. In Study 2, cDNA was synthesized with SuperScript1
VILO™ cDNA Synthesis Kit (Invitrogen) and gene expression determined in duplicates using
the TaqMan1 Fast Universal PCR Master Mix (ThermoFisher Scientific) (20 ng RNA/reac-
tion). Assay ID for each gene can be found in S4 Table. In study 1, gene expression for target
genes was normalized to the geomean of Rpl27, Rps13 and Ubc, while Rps13 was used in
study 2.
Flow cytometry analysis
Single cell suspension of aortic cells were achieved by cutting the aortas in small pieces and
incubating them in an enzyme cocktail containing 450 U/mL collagenase I, 125 U/mL
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collagenase XI, 60U/mL hyaluronidase, and 60 U/mL DNase I in PBS for 1 hour at 37˚C under
slow shaking. The digested aortas were passed through a 70 μM cell strainer, centrifuged at
1200 rpm for 5 min at 4˚ and resuspended in flow cytometry buffer (2% heat inactivated fetal
calf serum (HI FCS) and 2 mM EDTA in PBS w/o salts).
Prior to flow of kidney cells, the kidney/kidney remnant was carefully inspected and all
fat etc. was removed. In kidneys from SHAM operated mice, both poles were dissected away
to make sure that the kidney pieces from SHAM mice were anatomically comparable to the
kidney remnants from NX mice. Kidney pieces were weighed, cut into small pieces and incu-
bated in RPMI media (containing 5% FBS, 1% Pen/Strep, 50μM MeOH, 0,2% NaHCO3 10
mM Hepes and 1 mM Sodium pyruvate) supplemented with Collagenase (2 mg/mL) and
DNase (500 U/mL) for 40 min at 37˚C under slow rotation. Suspensions were then mixed
thoroughly and passed through a 100μM cell strainer. In Study 2, red blood cells were then
lysed using cell lysis buffer (eBioscience) due to insufficient perfusion of the mice. To digest
the glomerular structures, kidney suspensions were further incubated in RPMI (as described
above) supplemented with 50 mg/mL Collagenase, 50 mg/mL Dispase II, 500 U DNase and
0.25% Trypsin for 15 min. at 37˚C under slow rotation. The cells were then washed, centri-
fuged for 5 min at 1200 rpm at room temperature and resuspended in HBSS w/o salts with 2
mM EDTA and incubated for 10 min on ice. To disrupt tubular structures the suspensions
were passed through a long needle (70/0.63 mm 23G, SG) 3 times, and subsequently passed
through a 40 μM cell strainer. Finally, cells were centrifuged at 1200 rpm for 5 min and resus-
pended in flow buffer (2% heat inactivated fetal calf serum (HI FCS) and 2 mM EDTA in
PBS w/o salts).
For flow cytometry of both aortas and kidneys, cells were blocked for unspecific binding
with anti-CD16/CD32 (BD) and fixed and permeabilised using the Cytofix/Cytoperm solution
kit (BD Biosciences). Aorta cells were surface stained with CD45 (eBioscience), CD11b (Biole-
gend) and CD11c (BD Biosciences), all diluted in flow cytometry buffer, and intracellularly
stained for CD206 (AbdSerotic) diluted in permeabilizing buffer.
Kidney cells were surface stained with 7AAD, CD4 (BD Biosciences, San Jose, CA, USA),
CD45 (eBioscience), CD45, CD31, CD8a, F4/80 (Biolegend, San Diego, Ca, USA), ENAC (Ala-
mone, Jerusalem, Israel), CD8a, Ly6G, and Cd11c (BD- Pharmingen). Cells were intracellu-
larly stained for CD206 and CD68 (AbDSerotec). The cellular composition was analyzed on a
FACS LRSFortessa equipped with blue, red, and violet laser and data analysis was carried out
using FACSDiva software (BD).
Leukocytes were defined as CD45+ cells. Endothelial cells were defined as CD45-CD31+
cells. Distal tubular epithelial cells were defined as CD45-CD31- ENaC+ cells. Proximal tubular
epithelial cells were defined as CD45-CD31-ENaC- cells. Gating strategies for analyses of aortas
and kidneys are depicted in S8 and S9 Figs, respectively.
Histology
Kidneys were fixed in 4% formalin followed by paraffin embedding. 4 μm sections were sec-
tioned and stained with Massons trichrome using standard protocols and the following
reagents: Weigerts iron hematoxylin I and II (RH pharmacy, DK), Picric acid solution
(Sigma), Briebrich Scarlet solution (Difco laboratories), wolframphoshporic acid hydrate
(VWR) and methylene blue (Merck). The image analyses software Visiopharm (Visiopharm,
Denmark) was used to measure glomerular diameter and determine kidney fibrosis. The glo-
merular diameter was defined as the widest part of the glomerulus and at least 25 glomeruli
were measured per animal. Fibrosis was quantified automatically by Visiopharm as the blue
stained area in Masson’s trichrome stained sections in the kidney cortex.
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Statistical analysis
Statistical analyses were performed using GraphPad Prism 6.00 (GraphPad Software Inc., San
Diego). Comparisons were done with either Student’s t test or one-way ANOVA followed by
Sidak’s multiple comparisons post-test comparing SHAM with NX and NX with NX LIRA.
p< 0.05 was considered significant.
Supporting Information
S1 Fig. Study outline. In Study 1 LDLr-/- mice underwent 5/6 nephrectomy (NX) or SHAM
operation in a two-step procedure (week 1 and 3). Seven weeks later (week 10) the diet was
changed from chow to a western type diet, and the study was terminated 9 weeks later (week
19). In Study 2 LDLr-/- mice underwent 5/6 nephrectomy (NX) or SHAM operation in a two-
step procedure (week 1 and 3). Two weeks after the second operation (week 5) liraglutide treat-
ment was initiated and two weeks later (week 7) the diet was changed from chow to a western
type diet. After 11 weeks on the western type diet (week 18) the study was terminated. Blood
samples were collected just before initiation of liraglutide treatment, just before the diet was
changed, and eight weeks after initiation of liraglutide treatment).
(TIF)
S2 Fig. The number of endothelial cells and distal tubular epithelial cells is reduced in kid-
neys from uremic LDLr-/- mice. Sixteen weeks after induction of uremia, flow cytometry was
performed on kidneys from control (SHAM) and uremic (NX) LDLr-/- mice (n = 5 mice/
group). The number of endothelial cells (A), distal tubular cells (DTECs; B) and proximal
tubular cells (PTECs; C) relative to kidney weight is shown. Depicted values are mean±SEM.
p<0.05 as determined by unpaired students t-test. n = 5 mice per group.
(TIF)
S3 Fig. The number of leukocytes is not affected in kidneys from uremic LDLr-/- mice. Six-
teen weeks after induction of uremia, flow cytometry was performed on kidneys from control
(SHAM) and uremic (NX) LDLr-/- mice (n = 5 mice/group). The number of leukocytes was
analyzed by flow cytometry and normalized to kidney weight. Depicted values are mean±SEM.
Statistics were made by unpaired students t-test.
(TIF)
S4 Fig. Liraglutide treatment does not affect glucose levels in uremic mice. Glucose was
measured in plasma from non-fasted animals treated with liraglutide for eight weeks. To
obtain enough plasma for the measurement, plasma samples from two mice had to be pooled.
A total of seven pools were measured per group (one sample was excluded from the NX LIRA
group as the sample volume was too small). Depicted values are mean±SEM. Statistical analysis
were made by 1-way ANOVA followed by Sidak’s multiple comparisons post-test.
(TIF)
S5 Fig. Liraglutide treatment leads to a slight reduction in food intake in uremic mice.
Accumulated food intake was measured by weighing the food every day and normalizing it to
the number of mice in each cage. Depicted values are mean±SEM of 3 cages in each group.
(TIF)
S6 Fig. Liraglutide does not affect immune cell composition or gene expression in aortas
from uremic mice. A-D: flow cytometry analysis of aortas from control (SHAM; n = 6), ure-
mic (NX; n = 6) and liraglutide treated uremic (NX LIRA; n = 6) LDLr-/- mice after 11
weeks of treatment with full dose liraglutide (1000 μg/kg) showing the number of leukocytes
(A) and the myeloid (CD45+CD11b+) and lymphoid (CD45+CD11b-) cell distributions (B)
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as % of the leukocyte population. The mean fluorescence intensity of the M2 marker CD206
(C) and the M1 marker CD11c (D) was detected on myeloid cells. Depicted values are mean
±SEM. Statistical analysis were made by 1-way ANOVA followed by Sidak’s multiple com-
parisons post-test.
(TIF)
S7 Fig. NX leads to reduced levels of endothelial cells, proximal and distal tubular epithe-
lial cells and there is no effect of liraglutide. Fifteen weeks after induction of uremia, flow
cytometry was performed on kidneys from control (SHAM), uremic (NX), and liraglutide
treated uremic (NX LIRA) LDLr-/- mice (n = 7 mice/group). The number of endothelial cells
(A), distal tubular cells (B) and proximal tubular cells (C) relative to kidney weight are
depicted. Depicted values are mean±SEM. p<0.05, p<0.01, p<0.005 as determined by
1-way ANOVA followed by Sidak’s multiple comparisons post-test.
(TIF)
S8 Fig. The number of leukocytes in kidneys from NX mice tends to be reduced by liraglu-
tide. Fifteen weeks after induction of uremia, flow cytometry was performed on kidneys from
control (SHAM), uremic (NX), and liraglutide treated uremic (NX LIRA) LDLr-/- mice (n = 7
mice/group). The number of leukocytes in the kidney normalized to kidney weight is shown.
Depicted values are mean±SEM. p<0.05, p<0.01, p<0.005 as determined by 1-way
ANOVA followed by Sidak’s multiple comparisons post-test.
(TIF)
S9 Fig. Gating strategy for flow cytometry analysis of aortas. Cells were first gated according
to the forward and sideward scatter followed by detection of CD45+ cells in a CD45/Galectin-3
plot and adjusted in a FCS-A/SSC-A backgate. Galectin-3 was included as a macrophage acti-
vation marker and used here for optimal separation between populations, but not quantified
(data not shown). Finally lymphoid and myeloid cells were gated in a CD45/CD11b plot.
(TIF)
S10 Fig. Gating strategy for flow cytometry analysis of kidney cells. Kidney flow analysis
was performed using 3 antibody panels, detecting endothelial cells, DTECs and PTECs (A),
CD4+ and CD8+ T-cells (B) and monocyte-like and macrophage-like cells (C). In A, cells were
first gated according to the forward and sideward scatter. Then duplicates were removed in
first a FSC-H/FSC-W gate and then a SSC-H/SSC-W followed by removal of dead cells in a
7AAD/SCC-A plot. CD45+ cells were subsequently detected and excluded from further analy-
sis in a CD45+/SSC-A plot. The remaining cells were then gated for endothelial cells in a
CD31+/SSC-A plot followed by detection of ENAC+ cells in the CD45-CD31- population in a
FSC-A/ENAC+. In B, cells were first gated according to the forward and sideward scatter.
Then duplicates were removed in first a FSC-H/FSC-W gate, and then a SSC-H/SSC-W fol-
lowed by removal of dead cells in a 7AAD/FSC-A plot. CD45+ cells were subsequently deter-
mined by a CD45+/SSC-A plot and adjusted in a FCS-A/SSC-A backgate. Finally CD4+ and
CD8+ cells were gated in a CD4/CD8 plot. In C, cells were first gated according to the forward
and sideward scatter followed by removal of duplicates in first a FSC-H/FSC-W gate and then
a SSC-H/SSC-W. CD45+ cells were then detected in a CD45+/FSC-A plot and adjusted in a
FCS-A/SSC-A backgate. Finally a CD68/F4/80 plot was used to detect single positive
CD68+F4/80- and double positive CD68+F4/80- cells.
(TIF)
S1 Table. Plasma biochemistry data for study 1.
(PDF)
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S2 Table. Plasma biochemistry data for study 2.
(PDF)
S3 Table. NX leads to increased plasma cytokine levels, and there is no effect of liraglutide.
Plasma cytokine levels measured at termination of Study 2 are depicted as fold change of ure-
mic (NX) mice relative to control (SHAM) mice (black bars) and liraglutide treated uremic
mice (NX LIRA) relative to uremic (NX) mice (grey bars). Depicted values are mean±SEM.
Statistical analysis was made by 1-way ANOVA followed by Sidak’s multiple comparisons
post-test. p<0.05, p<0.01, p<0.005, p<0.001. n = 14–15 mice per group. OPN:
Osteopontin, MCP-1: Monocyte Chemoattractant Protein-1, TNFα: Tumor necrosis factor
alpha, KC: chemokine (C-X-C motif) ligand 1, IL-6: interleukin 6, IFNγ: interferon gamma,
IL-10: interleukin 10, IL-5: interleukin 5.
(PDF)
S4 Table. Primer ID list.
(PDF)
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